RecruitingNCT07105111
About this title
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Read the official source — NCT07105111Official study titleA Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Multiple locations, including BryantSchizophrenia, Depression, ...Medication studyAges 18+
- Countries
- United States
- Sponsor
- Neurocrine Biosciences (Biotech company)
RecruitingNCT07140913
About this title
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Read the official source — NCT07140913What is this study about?Researchers compare KarXT with placebo, each added to lithium, valproate or lamotrigine, in people with bipolarity type I experiencing mania, with or without mixed features. They want to know whether adding KarXT improves manic symptoms and assess its safety.
Multiple locations, including BentonvilleBipolarityMedication studyAges 18–65
- Countries
- United States, France, Argentina, + 10 others
- Sponsor
- Bristol-Myers Squibb (Pharmaceutical company)
RecruitingNCT07227454
What is this study about?This study evaluates the safety and effectiveness of Esketamine for people with depression.
Multiple locations, including BirminghamDepressionMedication studyAges 12–17
- Countries
- United States, Brazil, Hungary, + 4 others
- Sponsor
- Janssen Research & Development, LLC
RecruitingNCT06951698
About this title
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Read the official source — NCT06951698What is this study about?Researchers compare KarXT with placebo to find out whether it reduces manic symptoms in people with bipolarity type I. They also assess side effects and safety during treatment.
Multiple locations, including Little RockBipolarityMedication studyAges 18–65
- Countries
- United States, Australia, New Zealand, + 6 others
- Sponsor
- Bristol-Myers Squibb (Pharmaceutical company)
RecruitingNCT06951711
About this title
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Read the official source — NCT06951711What is this study about?Researchers compare KarXT with placebo during a three-week hospital treatment period for people with bipolarity type I experiencing mania, with or without mixed features. They assess changes in manic symptoms and monitor safety.
Multiple locations, including Little RockBipolarityMedication studyAges 18–65
- Countries
- United States, China, Croatia, + 8 others
- Sponsor
- Bristol-Myers Squibb (Pharmaceutical company)
RecruitingNCT07288567
What is this study about?Researchers are comparing KarXT and placebo to find out how the approaches affect psychotic symptoms in young people with schizophrenia.
Multiple locations, including AnaheimSchizophreniaMedication studyAges 13–17
- Countries
- United States, Colombia, Japan, + 1 other
- Sponsor
- Bristol-Myers Squibb (Pharmaceutical company)
RecruitingNCT07065240
About this title
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Read the official source — NCT07065240What is this study about?Researchers are comparing SPT-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Multiple locations, including ChinoDepressionMedication studyAges 18–65
- Countries
- United States, Bulgaria, Czechia, + 4 others
- Sponsor
- Seaport Therapeutics
RecruitingNCT06223880
About this title
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Read the official source — NCT06223880Official study titleA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
Multiple locations, including BellflowerDepressionMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Axsome Therapeutics, Inc.
RecruitingNCT07424404
Official study titleA Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride in Children and Adolescents With Psychiatric Disorders
Multiple locations, including AnaheimSchizophreniaMedication studyAges 5–17
- Countries
- United States, Australia, France, + 7 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
RecruitingNCT07196501
About this title
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Read the official source — NCT07196501Official study titleA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Multiple locations, including OceansideDepressionMedication studyAges 18+
- Countries
- United States, Australia, Canada, + 8 others
- Sponsor
- Neurocrine Biosciences (Biotech company)